Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC). The findings are based on the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress published in iThe New England Journal of Medicine/i.
EGFR mutations occur in 30-40% of NSCLC in Asian populations compared to 10-15% in Western populations. The phase III FLAURA trial compared osimertinib, a third generation ...
Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC). The findings are based on the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress published in iThe New England Journal of Medicine/i.
EGFR mutations occur in 30-40% of NSCLC in Asian populations compared to 10-15% in Western populations. The phase III FLAURA trial compared osimertinib, a third generation ...